Radnor, PA, – VWR Corporation (NASDAQ: VWR) announced the commencement of an underwritten public offering of 8,000,000 shares of its common stock by selling stockholder Varietal Distribution Holdings, LLC pursuant to a registration statement on Form S-3 filed with the Securities and Exchange Commission (the “Commission”). VWR will not receive any proceeds from this offering. In connection with the offering, the selling stockholder intends to grant the underwriters a 30-day option to purchase up to 1,200,000 additional shares.

Goldman, Sachs & Co. and Barclays are acting as joint book-running managers of the offering.

An automatic shelf registration statement relating to these securities was filed with the Commission on November 10, 2015 and became effective upon filing. The offering of these securities will be made only by means of a prospectus and prospectus supplement. You may obtain these documents for free by visiting EDGAR on the Commission’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About VWR Corporation

VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania, is a leading, global, independent provider of products, services and solutions to laboratory and production facilities. With sales in excess of $4.3 billion in 2015, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries. With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers’ productivity from research to production. VWR’s differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of approximately 9,300 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.